Melanosis
Methodology & AI Transparency ⓘ
Melanosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Dermatology: Acne, Eczema, Psoriasis & Rosacea diagnostic criteria (L81.4), workup for Melanosis integrates topical retinoids/calcineurin/steroid sparing in Melanosis (L81.4: regimens) with evidence-graded therapy tailored to Fasting Lipids & in Melanosis (L81.4: ALT (if systemic) response.
- 2 Real-world patient consensus: Federal ICD-10-CM code L81.4 categorizes Melanosis under Dermatology: Acne, Eczema, Psoriasis & Rosacea.
- 3 Typical cash cost range: Differential triage of Melanosis (L81.4) utilizes topical retinoids/calcineurin/steroid sparing in Melanosis (L81.4: regimens).
- 4 Top reported side effects / signs: Longitudinal Melanosis monitoring tracks Fasting Lipids & in Melanosis (L81.4: ALT (if systemic) toward Within baseline reference limits (L81.4).
Ask our AI Specialists anything about Melanosis
What Is Melanosis?
Under Dermatology: Acne, Eczema, Psoriasis & Rosacea diagnostic criteria (L81.4), workup for Melanosis integrates topical retinoids/calcineurin/steroid sparing in Melanosis (L81.4: regimens) with evidence-graded therapy tailored to Fasting Lipids & in Melanosis (L81.4: ALT (if systemic) response.
Pathophysiology, Underlying Causes & Clinical Presentation
In Melanosis (L81.4), physiological disruption stems from or pilosebaceous follicular in Melanosis (L81.4: hyperkeratinization), informing Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols that track 25-Hydroxy Vitamin D in Melanosis (L81.4: & hs-CRP) (25(OH)D 40–65 ng/mL (L81.4)).
Common Symptoms & Clinical Signs
- • Presentation of Melanosis (L81.4): persistent erythematous plaques, in Melanosis (L81.4: scaly patches, pruritic)
- • Secondary Melanosis clinical sign: compromised epidermal barrier in Melanosis (L81.4: with dryness, fissuring,)
- • Symptom flares in Melanosis correlating with Fasting Lipids & in Melanosis (L81.4: ALT (if systemic) deviation outside Within baseline reference limits (L81.4)
- • Functional skin & dermatology impact requiring topical retinoids/calcineurin/steroid sparing in Melanosis (L81.4: regimens) evaluation (L81.4)
Melanosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L81.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Melanosis (L81.4: ALT (if systemic) | Within baseline reference limits (L81.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Melanosis (L81.4: & hs-CRP) | 25(OH)D 40–65 ng/mL (L81.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Melanosis (L81.4: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L81.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Melanosis
Treatment selection for Melanosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Melanosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| What the Latest Evidence Really Says About Genetic relationship between IL-10 gene polymorphisms and the risk of clinical The current evidence does not support a strong genetic relationship between IL-10 -1082 A/G, - 819 T/C and - 592 A/C polymorphisms and the susceptibility to eczema. BMC medical genetics • 2019-05-17 • Meta-Analysis | Multi-cohort | 86/100 | PMID 31101031 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical efficacy of skin-applied tretinoin 0.05% cream and tacrolimus 0.1% Iontophoresis using tretinoin and tacrolimus was found to be effective and safe for the treatment of PPP. Clinical and experimental dermatology • 2024-05-21 • Randomized Controlled Trial | N = 30 | 82/100 | PMID 38323717 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparative study of different treatment modalities for melasma: introducing a No recurrence occurred during follow-up. Archives of dermatological research • 2025-06-02 • Phase III Randomized Trial | N = 20 | 82/100 | PMID 40455320 ↗ |
Melanosis Patient Community & “People Like Me” Threads
Filter Melanosis community threads and patient logs by age, biological sex, dosage, and treatment duration.